Samsung Biologics is confronting a mounting labor crisis that could potentially undermine its international standing in the pharmaceutical manufacturing sector. The company's labor union, representing approximately 60% of employees, has officially declared a breakdown in wage negotiations, citing systemic issues with workforce management and corporate governance.
The union has raised critical concerns about the company's cost-cutting strategies, which they argue are compromising production quality and internal labor conditions. An external mock inspection ahead of an upcoming FDA review revealed significant staffing shortages in production and quality control departments, increasing the risk of data integrity violations and potential human errors.
Global pharmaceutical clients are closely monitoring the escalating conflict, expressing explicit concerns about potential disruptions to contract continuity and production timelines. The labor union has additionally challenged Samsung Biologics' commitment to Environmental, Social, and Governance (ESG) principles, pointing to official labor inspection findings that confirmed multiple violations of the Labor Standards Act.
Despite Samsung Biologics' claims of limited financial capacity, the union argues that the company's substantial annual cash flows and retained earnings make their wage increase refusal untenable. The union has applied for official mediation and is preparing for potential large-scale demonstrations and a full-scale strike if negotiations do not progress constructively.
The ongoing dispute threatens to damage Samsung Biologics' global reputation, particularly in terms of ESG compliance and responsible corporate governance. The union has warned that continued uncooperative management attitudes could seriously undermine the company's international credibility and sustainable growth prospects.
